FindMyKOL
Clinical trialNCT04925089RecruitingObservational

Localized Leiomyosarcoma Biomarker Protocol

NCT04925089 is an observational study sponsored by University of Michigan Rogel Cancer Center. As of 21 Nov 2026, it is recruiting participants. It studies Leiomyosarcoma. The registry lists an enrollment of 40 participants at 3 sites in 1 country. The registry lists a start date of 26 Apr 2023 and a primary completion date of 30 Nov 2026. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04925089
FieldValue
Registry IDNCT04925089
StatusRecruiting
Study typeObservational study
Lead sponsorUniversity of Michigan Rogel Cancer Center
Enrollment40
Registered sites3
Countries1
ConditionsLeiomyosarcoma
Start26 Apr 2023
Primary completion30 Nov 2026
Study completion30 Nov 2026
Last update posted2 Jul 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

* Leiomyosarcoma (LMS) is one of the more common soft tissue sarcomas (STS). * Patients presenting with large, high-grade, localized LMS are at significant risk of developing metastasis following curative surgery. * Clinical trials of neoadjuvant or adjuvant anthracycline and ifosfamide have suggested that patients with localized STS who are at high-risk of metastasis may benefit from chemotherapy, but the magnitude of benefit in unselected patient population is relatively small. * Currently, patient age, and tumor size and grade are used to assess risk of metastases and survival * Studies evaluating tumor response by imaging and histopathology have not established correlation between tumor characteristics as biomarkers for risk of metastasis or sarcoma recurrence. * Circulating tumor DNA (ctDNA) is present in blood of patients with advanced/metastatic LMS and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to, during and after chemotherapy and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Patients will be followed for 2 years after study entry for signs of sarcoma recurrence. * A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Michigan, United States1 site, 1 recruiting
  • University of Michigan

    Ann Arbor

    Recruiting
Minnesota, United States1 site, 1 recruiting
  • Mayo Clinic

    Rochester

    Recruiting
Tennessee, United States1 site, 1 recruiting
  • Vanderbilt University Medical Center

    Nashville

    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesota: 1 site, 1 recruitingMN1WisconsinWIMichigan: 1 site, 1 recruitingMI1New YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennessee: 1 site, 1 recruitingTN1North CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT04925089

Each answer restates registry values shown on this page.

What is NCT04925089?

NCT04925089 is an observational study sponsored by University of Michigan Rogel Cancer Center. It studies Leiomyosarcoma.

Is NCT04925089 recruiting?

As of 21 Nov 2026, it is recruiting participants. 3 of its 3 sites list their own status as recruiting.

Who leads NCT04925089?

The registry names Scott Schuetze (principal investigator, University of Michigan Rogal Cancer Center) as the overall official.

Where does NCT04925089 run?

The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.

When is NCT04925089 expected to complete?

The registry lists a primary completion date of 30 Nov 2026 and a study completion date of 30 Nov 2026. The sponsor last updated the record on 2 Jul 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.